Efficiency and safety of cinobufacini in treating refractory thrombocytopenic purpura

Objective Study on the efficiency and safety of cinobufacini in treating refractory thrombocytopenic purpura. Methods This study collected 100 cases from hematology department of First Affiliated Hospital of Guangzhou University of Chinese Medicine during the time from January,2012 to January,2013. The cases were randomly divided into the experimental group of 30 cases( using cinobufacini) and the control group of 30 cases( using danazol). The control group and the experimental group were treated with danazol and cinobufacini respectively for 12 weeks. Results After the treatment,the expression of CD4+ T cells and CD4+ CD25+ Treg / CD4+ cells of experimental group was 33. 5 ± 4. 1 and 11. 4 ± 3. 4. Comparing with the data of experimental group before treatment( 17. 2 ± 3. 4)( 3. 0 ± 0. 4) and control group( 25. 3 ± 6. 2)( 6. 2 ± 1. 5),the difference was statistically significant( P 0. 05). The amount of blood platelet( 112. 3 ± 11. 7) increased notably. Comparing with the number before treatment,the difference was statistically significant( P 0. 05). Overall response rate( 100%) was higher than that of the control group( 83. 4%),the difference was statistically significant( P 0. 05). There was hardly any serious complications. Conclusion Cinobufotalin could improve the abnormal activation of autoimmune T cells of the patients and adjust T cell subgroup. It is safe and effective in the treatment of refractory thrombocytopenic purpura.